New combo therapy for rare lung cancer shows early promise
NCT ID NCT02959463
First seen Nov 14, 2025 · Last updated Apr 24, 2026 · Updated 20 times
Summary
This early-stage trial studies the safety of giving the immunotherapy drug pembrolizumab after radiation therapy for people with malignant pleural mesothelioma, a rare cancer of the lung lining. The study enrolled 24 adults whose cancer was confirmed by biopsy. The main goal is to see if the combination causes severe side effects, and researchers also track how long patients live and how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL MALIGNANT MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.